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Abstract
Bone marrow fibrosis is the continuous replacement of blood-forming cells in the bone marrow with excessive
scar tissue, leading to failure of the body to produce blood cells and ultimately to death. Myofibroblasts are
fibrosis-driving cells and are well characterized in solid organ fibrosis, but their role and cellular origin in
bone marrow fibrosis have remained obscure. Recent work has demonstrated that Gli1+ and leptin receptor+
mesenchymal stromal cells are progenitors of fibrosis-causing myofibroblasts in the bone marrow. Genetic
ablation or pharmacological inhibition of Gli1+ mesenchymal stromal cells ameliorated fibrosis in mouse models
of myelofibrosis. Conditional deletion of the platelet-derived growth factor (PDGF) receptor- (PDGFRA) gene
(Pdgfra) and inhibition of PDGFRA by imatinib in leptin receptor+ stromal cells suppressed their expansion and
ameliorated bone marrow fibrosis. Understanding the cellular and molecular mechanisms in the haematopoietic
stem cell niche that govern the mesenchymal stromal cell-to-myofibroblast transition and myofibroblast expansion
will be critical to understand the pathogenesis of bone marrow fibrosis in both malignant and non-malignant
conditions, and will guide the development of novel therapeutics. In this review, we summarize recent discoveries
of mesenchymal stromal cells as part of the haematopoietic niche and as myofibroblast precursors, and discuss
potential therapeutic strategies in the specific targeting of fibrotic transformation in bone marrow fibrosis.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Bone marrow fibrosis
Bone marrow (BM) fibrosis is the continuous replace-
ment of blood-forming cells in the BM by excessive
scar tissue, leading to failure of the body to pro-
duce blood cells and ultimately to death. A number
of haematological and non-haematological disorders
are associated with increased BM fibrosis, including
myelodysplastic syndromes and myeloproliferative
neoplasms (MPNs) [1].
Primary myelofibrosis (PMF) is the prototypical
example of progressive development of BM fibrosis and
progressive evolution of BM insufficiency. PMF refers
to BCR-ABL1-negative MPN, and is a clonal disorder
of haematopoiesis arising in the haematopoietic stem
cell (HSC) [2]. The majority of patients with PMF carry
mutations that activate JAK–STAT signalling; 60%
harbour the JAK2V617F mutation, approximately 30%
carry a calreticulin (CALR) mutation, and 8% carry a
myeloproliferative leukaemia virus oncogene (MPL)
mutation [3–8]. PMF is the most aggressive of the
three classic MPNs, and is associated with significantly
shortened survival [9,10]. Despite our advanced under-
standing of the molecular pathogenesis of malignant
myeloid diseases, the stepwise pathogenesis of BM
fibrosis is poorly understood. Up to just a few months
ago, the cells that drive BM fibrosis remained obscure,
impeding the cellular and molecular dissection of this
process. The recent discovery of Gli1+ and leptin recep-
tor (LepR)+ stromal cells, which are cells of the HSC
niche, as fibrosis-driving cells in the BM opens new
avenues for investigation of the molecular and cellular
mechanisms of fibrotic transformation. Accumulating
evidence suggests that PMF is not only a disease of
HSCs and haematopoietic progenitor cells, but is rather
a disease of the entire HSC niche. The data presented in
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this review provide a rationale for dissecting the interac-
tion between HSCs and haematopoietic progenitor cells
and their complex microenvironment in more detail,
and for evaluating the role of different niche cells in
both malignant and non-malignant diseases leading to
BM fibrosis.
Stromal cell populations in the BM
microenvironment (the HSC niche)
The emerging picture of the BM niche is that of a
complex and multifaceted collection of regulatory cell
types, with important roles in bone formation and the
maintenance of HSC function and blood production
regulation. Several stromal cell populations are impli-
cated in the regulation of haematopoiesis, and recent
studies have highlighted the role of specific stromal cell
populations in regulating discrete haematopoietic pro-
genitor populations [11–13]. BMmesenchymal stromal
cells (MSCs) constitute a rare population of cells found
around arterioles and sinusoid vessels, and are in direct
contact with endothelial cells; others are located in
the endosteal niche adjacent to the bone [14]. Early
studies of BM MSCs and cells responsible for HSC
support implicated mature bone-forming osteoblasts,
which produce granulocyte colony-stimulating factor,
thrombopoietin (TPO), and CXC motif ligand (Cxcl) 12
[15]. It was further shown that differentiating osteoblas-
tic lineage cells (OBCs) express many factors that
are important for HSC function, including Cxcl12,
stem cell factor (SCF) (also termed c-KIT ligand or
Steel factor), and angiopoietin-1 (ANGPT1), as well
as extracellular matrix (ECM) proteins such as osteo-
calcin, collagen 1, and osteopontin (Figure 1) [16,17].
In particular, MCAM/CD146-expressing subendothe-
lial stromal cells with osteogenic potential (so-called
self-renewing osteoprogenitor cells) are major produc-
ers of ANGPT1, a central molecule of the HSC ‘niche’
involved in vascular remodelling [18,19]. The expansion
of osteolineage cells results in increased HSC numbers,
whereas their ablation results in HSC loss in the BM
and extramedullary haematopoiesis [20,21]. However,
their true contribution to HSC maintenance remains
controversial, as deletion of Cxcl12 or Scf from mature
osteoblasts has no effect on HSCs, probably indicating
heterogeneity within the osteolineage cell population.
Importantly, although mature osteolineage cells appear
to have limited roles in vivo, immature osteolineage cells
may have a greater impact on HSCmaintenance [22,23].
The perivascular location of HSCs highlighted the
importance of stromal cells in the perivascular area
as crucial BM niche components with a significant
HSC-supporting function [24]. Within the perivascular
region, a large proportion of stromal cells express high
levels of Cxcl12, which plays a crucial role in maintain-
ing HSC function. So far, three stromal cell populations
characterized by high Cxcl12 expression have been
identified: (1) Cxcl12-abundant reticular (CAR) cells
[25,26]; (2) nestin (Nes)+ MSCs (Nes-MSCs) [27];
and (3) leptin receptor (LepR)+ stromal cells (Figure 1)
[28,29]. It is likely that there is considerable overlap
between these populations. CAR cells are mesenchymal
progenitors with adipogenic and osteogenic potential
in vitro [26]. Importantly, their conditional ablation
with diphtheria toxin and the Cxcl12-regulatory ele-
ment resulted in a reduction in HSC numbers and
long-term repopulation activity, alongside increased
HSC quiescence [26]. Nes-MSCs express the classic
mesenchymal-specific markers platelet-derived growth
factor receptor-α (PDGFRA/CD140a), CD51, and Sca-1
[30,31], as well as LepR [32] and the pericyte marker
neuron/glial antigen 2 (NG2) [33]. Although there is
significant functional overlap betweenMSC populations
defined with these markers in terms of multipotency
and self-renewal capacities, their distribution in the
BM cavity and their association with the endosteum or
blood vessels are distinct [13,24]. NG2+LepR+Nesdim
pericyte-like MSCs are mainly periarteriolar in local-
ization, and are close to the endosteal bone surface.
NG2+LepR+Nesbright reticular-like MSCs are mostly
perisinusoidal in localization, and are located more in
the central BM cavity, away from the endosteum [33]
(Figure 1). Perivascular MSCs are directly involved
in maintaining HSCs in the BM niche, as shown by
a series of studies investigating the consequence of
either Nes-mediated or Cxcl12-mediated MSC ablation
[26,27] or Lepr-mediated or Prx1-mediated deletion
of Scf and Cxcl12 expression in MSCs [22,23,29].
Nes-MSCs also express genes that are important for
HSC maintenance, such as Cxcl12, Scf , and ANGPT1,
although their ablation results in a minor loss of
HSCs within the BM [11]. Much like CAR cells and
Nes-MSCs, LepR+ stromal cells express high levels
of Cxcl12 and SCF, highlighting large overlapping
stromal cell populations. Interestingly, CAR cells also
express high levels of LepR. Intriguingly, osteoblasts
were not targeted by Lepr:Cre in lineage mapping
studies, suggesting the presence of a LepR– CAR cell
subpopulation with osteogenic potential.
Evidence suggests that dysregulation of the interac-
tion between HSCs and haematopoietic progenitor cells
and distinct stromal cell populations, either in malignant
haematopoietic diseases or in inflammatory processes,
disrupts the tightly regulated process of haematopoiesis
in the BM niche and favours a secretory phenotype of
stromal cells with decreased haematopoiesis-supporting
capacity.
Stromal cell populations in BM fibrosis
Recent studies using different models of haematopoi-
etic malignancies associated with BM fibrosis were
able to mechanistically elucidate how malignant
haematopoietic cells and proinflammatory cytokines
activate stromal cells in the BM, support their fibrotic
and secretory activity, and influence their reduced
haematopoiesis-supporting capacity (Figure 2).
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Figure 1. The HSC niche in homeostasis: a simplified overview of the HSC niche with a focus on different MSC subsets under homeostatic
conditions. Different mesenchymal precursor cells are shown in their localizations in the BM cavity. Relevant secreted and/or cell-bound
factors that regulate HSC functional states are highlighted. EPO, erythropoietin; GFP, green fluorescent protein; NorE, norepinephrine.
Two recent studies showed that malignant
haematopoietic cells in murine models of MPN [34]
and acute myeloid leukaemia (AML) [35] can dam-
age Nes-MSCs and nerve cells. In these models, the
development of haematological malignancy created
neuropathic changes in the BM niche, which affected
the activity of perivascular MSCs and altered the
function of the HSC niche. In particular, they demon-
strated that inflammatory mechanisms mediated by the
malignant haematopoietic cells affect the dysregula-
tion of Nes-MSCs. JAK2V617F-mutated HSCs and
haematopoieticprogenitor cells in the murine MPN
model led to interleukin (IL)-1-mediated damage to
nerve fibres and Nes-MSCs. The subsequent loss of
Nes-MSCs led to an accelerated MPN phenotype
through neuropathic changes and to complete dis-
ruption of normal haematopoiesis [34]. Interestingly,
Jak2V617F MPN mice develop BM fibrosis despite
a reduction in the size of the MSC compartment with
loss of Nes-MSCs. As in the MPN model, leukaemic
cells in an MLL-AF9 AML transplantation model
caused losses of periarteriolar NG2+ cells and nerve
fibres, resulting in a sympathetic neuropathy. In this
model, an abnormal population of Nes-MSCs expanded
with skewed osteoblastic differentiation and down-
regulated expression of many HSC retention factors,
including Cxcl12 and SCF, but BM fibrosis was not
detectable [35]. Together, these studies indicate that
MPN-induced and AML-induced neuropathy pro-
motes the development of a self-reinforcing malignant
niche that favours disease development at the expense
of normal HSC maintenance. These studies further
demonstrate that Nes-MSCs are not fibrosis-driving
cells in BM fibrosis, although their reduction and sub-
sequent neuropathy in the BM most likely contribute to
dysregulated haematopoiesis and disease progression.
The aberrant differentiation of Nes-MSC in
osteoblasts under leukaemic conditions highlights
the role of the endosteal bone in regulation of the BM
niche and disease progression. In this context, Schepers
et al demonstrated that OBCs, derived from multipotent
stromal cells, expand in the presence of malignant
haematopoietic cells, resulting in matrix production and
trabecular thickening [17]. Similarly to the findings of
aberrant osteogenic differentiation of Nes-MSCs in the
presence of AML cells, they showed that BCR-ABL+
malignant haematopoietic cells stimulate MSCs to
proliferate and adopt an abnormal differentiation pro-
gramme, resulting in the overproduction of functionally
altered OBCs, which accumulate in the BM cavity as
inflammatory myelofibrotic cells. Myelofibrotic OBCs
also express proinflammatory cytokines (i.e. IL-1 and
tumour necrosis factor-α), which probably amplify
disease development and aberrant myeloid cell produc-
tion. In summary, these three studies using different
models of myeloid malignancies led to the hypothesis
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Figure 2. Stromal cell populations in the HSC niche in BM fibrosis: overview of the HSC niche in BM fibrosis with a focus on the contribution
of different MSC populations to disease initiation and progression. Different MSC populations and precursors of myofibroblasts contribute
to BM fibrosis by different mechanisms and cytokines, and secreted and/or cell-bound factors. Dysplastic megakaryocytes are supposed to
play a central role in the initiation of BM fibrosis. GFP, green fluorescent protein; ROS, reactive oxygen species.
that the HSC niche is an oncogenic unit that promotes
malignant haematopoiesis at the expense of normal
haematopoiesis in terms of a self-reinforcing niche
[17,36]. These studies also highlight the significant role
of inflammation in the disturbance of the haematopoi-
etic niche in myeloid malignancies, in particular in the
initiation of BM fibrosis (Figure 2).
However, these studies did not identify
fibrosis-driving cells. The identification of cells that
drive the development of a fibrotic BM niche with
its detrimental consequences for the maintenance
of HSCs is a prerequisite for the development of
novel targeted therapeutics. Two recent studies using
state-of-the-art techniques including genetic fate tracing
in vivo, including our own work, provided evidence that
LepR+ and Gli1+ cells are key players in the initiation
and progression of BM fibrosis [28,37]. Decker et al
demonstrated that BM LepR+ mesenchymal stromal
lineage cells expand extensively and are fibrogenic in
PMF [28]. LepR+ MSCs downregulate the expression
of key HSC-supporting factors and upregulate genes
associated with fibrosis and osteogenesis, indicating
fibrogenic conversion. On the basis of this finding,
Decker et al suggested that targeting PDGFRA sig-
nalling might be an attractive strategy for treating BM
fibrosis. Their data demonstrated that administration of
imatinib or conditional deletion of Pdgfra from LepR+
stromal cells suppresses their expansion and ameliorates
BM fibrosis (Figure 2). We recently demonstrated that
the hedgehog (Hh) transcriptional activator Gli1 marks
perivascular MSCs, which contribute substantially to
organ fibrosis and constitute a relevant therapeutic
target to prevent solid organ dysfunction after injury
[38]. Gli1+ cells show MSC functional characteristics.
The identification of perivascular Gli1+ MSC-like cells
as a major cellular origin of organ fibrosis provided a
rationale for studying Gli1+ cells in the BM [38,39].
Periarteriolar Gli1+ cells in the BM have similarities to
Nes-MSCs, but do not express LepR. The majority of
Gli1+ cells in the endosteal niche are not associated with
glial fibrillary acidic protein+ glia or sympathetic nerve
fibres, and only partially express Nes [37]. Thus, they
might represent a distinct subpopulation of stromal cells
in the BM.
Using genetic fate tracing experiments in two murine
models of BM fibrosis, we demonstrated that Gli1+
MSCs are fibrosis-driving cells of the BM (Figure 2).
They are recruited from their endosteal and perivas-
cular niche in the presence of mutated haematopoietic
cells to become α-smooth muscle actin (α-SMA)+
fibrosis-driving myofibroblasts [37]. Importantly, the
genetic ablation of Gli1+ cells completely abolishes
BM fibrosis and rescues BM failure, providing func-
tional proof that these cells are drivers of the fibrotic
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transformation. Upon myelofibrotic transformation,
Gli1+ cells significantly expand in the BM, in both
murine models and patient samples, whereas Nes+
cells decrease in number, suggesting that neuropathic
changes lead to dysregulation of the niche accom-
panied by enhanced expansion and myofibroblast
differentiation of Gli1+ MSCs [37].
Importantly, both LepR+ and Gli1+ stromal cells
differentiate into myofibroblasts in BM fibrosis, and
their differentiation seems to be the common down-
stream mechanism. Across different organ systems, the
majority of investigators agree that myofibroblasts are
fibrosis-driving cells; however, the functional contri-
bution of myofibroblasts in BM fibrosis has remained
elusive. Only a few electron-microscopy studies from
the last century and more recent immunohistochemical
staining suggested an increase in the number of myofi-
broblasts in human BM fibrosis [40–42]. The recent
genetic fate tracing data studies have shown that both
Gli1+ and LepR+ stromal cells are progenitors of myofi-
broblasts in BM fibrosis. The fact that genetic ablation
of Gli1+ cells abolishes BM fibrosis and restores
haematopoiesis indicates that Gli1+ MSCs constitute a
promising cellular therapeutic target. An open question
to be answered in future experiments is which factors
and pathways induce the differentiation of multipo-
tent stromal cells into fibrosis-driving myofibroblasts.
Lessons could be learned frommechanisms identified in
solid organ fibrosis. Furthermore, it remains elusive how
heterogeneous the stromal population is, and whether
there is an overlap of Gli1+ and LepR+ cells. Another
open question is how the identified cell populations
compare with CD146+, SPARC-expressing cells, which
also were shown to react to myeloproliferative stimuli
[43,44]. Future single-cell resolution studies will shed
light on this interesting topic.
Similarities to solid organ
fibrosis – proinflammatory cytokines
and platelets as common mechanisms
Fibrosis as a broad term describes the excess deposi-
tion of ECM elements that normally form a complex
network of collagens, laminins, entactin, heparan
sulphate and other proteoglycans. Fibrosis is often
defined as a wound-healing response and repair of
damaged tissues that has got out of control. Damage to
tissues can result from various acute or chronic stim-
uli, including, but not limited to, infections, hypoxia,
hypertension, diabetes, autoimmune reactions, and
mechanical injury. BM fibrosis is seen in a variety of
malignant (e.g. multiple myeloma and myelodysplastic
syndrome) and non-malignant (e.g. chronic autoim-
mune diseases, infections, and exposure to radiation or
toxins) disease states. It is likely that both malignant
and non-malignant diseases activate fibrosis-driving
cells by common downstream mechanisms. PMF is the
best-studied haematopoietic malignancy inducing BM
fibrosis, and is often used as the prototypic example of
BM fibrosis.
In PMF patients, the haematopoietic phenotype
is characterized by a progressive dominance of
malignant (clonal) haematopoiesis over normal poly-
clonal haematopoiesis, the abnormal proliferation of
megakaryocytes, the deposition of ECMmaterial within
the BM, extensive extramedullary haematopoiesis,
abnormal stem cell trafficking, and shortened survival
[45–48]. The pathognomonic hyperplasia and dysplasia
in the megakaryocyte lineage also results in the exces-
sive production of cytokines and chemokines, such as
fibroblast growth factor (FGF), within the BM, and
reticulin and collagen fibre deposition in the BM space
are additional cardinal signs of disease (Figure 2). This
ECM accumulation is supposed to be driven by the
extramedullary release of cytokines by the malignant
haematopoietic clone and by dysplastic megakaryocytes
derived from the malignant clone [49]. Growth factors
such as PDGF, βFGF and transforming growth factor
(TGF)-β are thought to activate fibrosis-driving cells,
triggering the progressive process of myelofibrosis
(MF), and βFGF, vascular endothelial growth factor
(VEGF) and IL-8 can activate endothelial cells that
contribute to neoangiogenesis [50]. Hence, it is hypoth-
esized that the cross-talk between HSCs and stromal
cells is altered. In this scenario, malignant HSCs release
growth factors that condition stromal cells and allow
them to gain novel properties. These events subse-
quently create a pathological microenvironment that
allows the malignant clone to develop, leading to imbal-
ances that compromise normal haematopoiesis [45].
Therefore, HSC niche deregulation is a key step in
myeloproliferative processes.
The common downstream mechanisms in fibrotic
transformation in solid organs and in the BM (induced
by both malignant and non-malignant haematopoiesis)
appear to be inflammatory programmes and the involve-
ment of megakaryocytes and/or platelets. In solid organ
fibrosis, platelets play an important role in the initiation
of fibrosis. Platelets are exposed to ECM components,
triggering aggregation, clot formation, and haemostasis.
Platelet degranulation subsequently promotes vasodila-
tion and increased blood vessel permeability, while also
activating myofibroblasts (collagen-secreting α-SMA+
fibroblasts) [51]. As described above, megakaryocytes
also seem to have a driving and initiating role in BM
fibrosis, in particular through the secretion of proin-
flammatory and profibrotic cytokines. In solid organ
fibrosis, CXC chemokines play a significant role in the
activation and migration of myofibroblasts and fibro-
cytes. In particular, CXC chemokine receptor (CXC)
4, CC chemokine receptor (CCR) 7 and CCR2 mediate
the recruitment of myofibroblasts and, potentially, their
differentiation. A central role of platelet-derived Cxcl4
(also known as platelet factor 4) was demonstrated in
solid organs. It was shown that Cxcl4 is secreted not
only by activated platelets, but also by plasmacytoid
dendritic cells and fibroblasts [52,53]. These stud-
ies link megakaryocytes/platelets to proinflammatory
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programmes and the activation of profibrotic pro-
grammes in fibrosis. In MF, studies performed 30 years
ago indicated that abnormal megakaryocytes stimulate
the proliferation of fibrosis-driving fibroblasts, par-
tially mediated by Cxcl4 [54]. Functional and gene
expression studies using RNA sequencing recently
demonstrated that Cxcl4 also induces migration of
Gli1+ stromal cells and their myofibroblast transdif-
ferentiation, thus mediating central cellular processes
in BM fibrosis (Figure 2). Significant downregulation
of the chemokine stromal-cell derived factor (SDF)-1
(Cxcl12) was also observed, in line with previous
studies characterizing niche cells in MPN [17,34].
Interestingly, deletion of Cxcl12 in stromal cells was
shown to increase the number of circulating platelets
[34,55], and studies in patients with MF have suggested
that the BM microenvironment is deprived of active
Cxcl12 [56]. These data led to the hypothesis that Gli1+
stromal cells are activated from their niche by atypical
platelets/megakaryocytes (mediated by Cxcl4), which
leads to a cascade of myofibroblast transdifferentia-
tion, metabolic reprogramming, and downregulation
of Cxcl12. Additional stimuli might be derived from
mutant neutrophils that additionally lead to persistent
immune stimulation [57].
Implications for the therapy of BM
fibrosis – treating the deregulated HSC niche
At present, the only curative treatment modality for PMF
is allogeneic stem cell transplantation, which is able to
restore BM function but carries significant risks of mor-
bidity andmortality, particularly in the older patient pop-
ulation [58,59]. It is hypothesized that myeloid malig-
nancies such as PMF can be worsened by deregulation
of the BM microenvironment [60], including MSCs and
their progeny.
We will focus here on a discussion of treatment strate-
gies for PMF, as the treatment of BM fibrosis induced
by other malignant and non-malignant processes in the
BM is even less well understood and is understudied.
The potential therapeutic approaches for PMF can be
divided into two categories: (1) eradication of the malig-
nant haematopoietic clone; or (2) targeting BM fibrosis.
Currently, no Food and Drug Administration-approved
therapies exist for specific targeting of the fibrotic BM
niche, although reversal of BM fibrosis is a clinically
achievable goal, as demonstrated in chronic myeloid
leukaemia (CML) patients upon BCR/ABL inhibition
[61] or in PMF patients upon SCT [62–64]. With the
introduction of selective JAK inhibitors over the last
10 years, initial expectations of clonal suppression as
measured by elimination of molecular and karyotypic
abnormalities were dampened by the observations of
persistent clonal haematopoiesis and unaltered MPN
BM pathological features. Although JAK inhibitors
improve patient constitutional symptoms and reduce
splenomegaly, JAK inhibitor monotherapy does not
Figure 3. Hh–Gli signalling in myofibroblasts. The canonical Hh
pathway is characterized by binding of one of the three ligands
desert hedgehog (Dhh), Indian hedgehog (Ihh) or sonic hedgehog
(Shh) to the receptor Ptch1, which discontinues its tonic inhibi-
tion on the transmembrane protein smoothened (Smo) upon ligand
binding. Smo then activates the transcriptional activators of Hh sig-
nalling, the so-called Gli proteins, which will transfer to the nucleus
and activate expression of Hh target genes, promoting expansion of
myofibroblasts and fibrosis. Non-canonical Hh signalling can acti-
vate Gli proteins directly and independently of the Hh ligands Ptch1
and Smo.
significantly reduce the mutant allele burden in the
majority of MPN patients [65–67].
Increases in the expression of Hh target genes has
been observed in granulocytes isolated from MPN
patients [68]. So far, the exact role of the Hh pathway
in PMF and its contribution to BM fibrosis is not fully
understood. We have shown that Gli1 expression is
significantly increased in stromal cells from MPN
patients (Figure 3). Pharmacological targeting with the
Gli inhibitor GANT61 inhibits Gli1+ cell expansion and
myofibroblast differentiation, and attenuates fibrosis
severity [37]. These data thus provide a rationale for
targeted therapy of Gli proteins in BM fibrosis, as
monotherapy or combined therapy with other agents.
The efficacy of Gli inhibition in murine BM fibrosis
models further suggests that combinations of JAK2
inhibitors with inhibitors of the Hh pathway might
provide a novel avenue for targeting stem cell-derived
clonal myeloproliferation (which evades JAK2-targeted
monotherapy). Preclinical and clinical data suggest
that Hh pathway inhibitors have therapeutic activity in
MF. To date, only Smo inhibitors have been tested in
MF, with varying success [69]. We hypothesize that
Gli proteins in Gli1+ cells can be activated indepen-
dently of canonical Hh signalling, explaining the mixed
response in patients with MF, e.g. by phosphoinositide
3-kinase–AKT signalling (Figure 3).
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Strategies aimed at preventing the development
of a profibrotic niche could help to restore nor-
mal haematopoiesis and disrupt the malignant
self-reinforcing niche. Several agents are expected to
target the microenvironment, including immunomodu-
latory drugs such as thalidomide and lenalidomide,
proteasome inhibitors such as bortezomib, and
VEGF-targeting drugs such as sunitinib and beva-
cizumab, and have been tested in subsets of PMF
patients. However, these clinical trials have had mixed
results, and were hampered by severe tolerability issues
[70]. Considering the importance of inflammatory
cytokines in driving fibrotic BM niche remodelling [17]
and CML development [71] in murine models, it will
be crucial to test the effect of blocking these specific
proinflammatory cytokines with various suppressing,
neutralizing and/or antagonizing antibodies that are
currently available for clinical use. Strategies aimed
at either directly protecting nerve cells in the BM or
at preserving their interaction with perivascular MSCs
[34,35] might also help to support the maintenance
of normal haematopoeisis. The experimental evidence
that the clinically approved β3-adrenergic agonist
mirabegron delays disease onset and improves several
MPN-associated features in the Jak2V617F murine
MPN model [34] provides a rationale for modulating
nerve cells in BM fibrosis.
Summary
BM fibrosis is a reactive secondary process and a cardi-
nal feature of PMF. Identifying Gli1+ and LepR+ cells
as the sources of fibrosis-driving cells was the first cru-
cial step in developing antifibrotic therapies. As we
have discussed, there is significant overlap in the stro-
mal cell populations that contribute to HSCmaintenance
and to the development of haematological malignancies.
Importantly, we have identified Gli1+ cells as a stromal
cell population that provides an attractive therapeutic
target, and have also identified deregulated pathways in
these cells that provide novel avenues for future targeted
therapies [37,38].
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